Celularity (CELU) Assets Average (2019 - 2025)
Celularity (CELU) posted quarterly Assets Average of $57.3 million for Q4 2025, down 56.19% year-over-year from $130.8 million in Q4 2024, and down 51.15% quarter-over-quarter from $117.3 million in Q3 2025.
Celularity (CELU) Assets Average (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Assets Average for 7 consecutive years, with $57.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average fell 56.19% year-over-year to $57.3 million; the TTM figure through Dec 2025 stood at $57.3 million (down 56.19% YoY), while the FY2025 annual figure was $66.5 million, down 51.9% from the prior year.
- Assets Average declined to $57.3 million in Q4 2025 per CELU's latest filing, from $117.3 million in the prior quarter.
- Across five years, Assets Average topped out at $433.2 million in Q3 2022 and bottomed at $57.3 million in Q4 2025.
- Historically, Assets Average has averaged $250.7 million across 5 years, with a median of $206.0 million in 2021.
- Annual changes were most pronounced in 2022 — Assets Average soared 105.44% — and 2023, when it sank 64.08%.
- Celularity's Assets Average stood at $431.2 million in 2021, then declined by 2.81% to $419.1 million in 2022, then tumbled by 64.08% to $150.5 million in 2023, then dropped by 13.14% to $130.8 million in 2024, then slumped by 56.19% to $57.3 million in 2025.
- Business Quant data shows CELU's Assets Average at $57.3 million in Q4 2025, $117.3 million in Q3 2025, and $124.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Celularity | 20.90 Mn | 14.72 Mn | -3.27 Mn | 57.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 57.29 Mn |
| Sep 30, 2025 | 117.26 Mn |
| Jun 30, 2025 | 124.58 Mn |
| Mar 31, 2025 | 130.78 Mn |
| Dec 31, 2024 | 130.76 Mn |
| Sep 30, 2024 | 132.17 Mn |
| Jun 30, 2024 | 139.66 Mn |
| Mar 31, 2024 | 143.85 Mn |
| Dec 31, 2023 | 150.54 Mn |
| Sep 30, 2023 | 201.81 Mn |
| Jun 30, 2023 | 304.42 Mn |
| Mar 31, 2023 | 381.74 Mn |
| Dec 31, 2022 | 419.09 Mn |
| Sep 30, 2022 | 433.23 Mn |
| Jun 30, 2022 | 431.77 Mn |
| Mar 31, 2022 | 424.17 Mn |
| Dec 31, 2021 | 431.21 Mn |
| Sep 30, 2021 | 288.35 Mn |
| Jun 30, 2021 | 210.17 Mn |
| Mar 31, 2021 | 361.47 Mn |